Private Equity interview preparation

Questions

100

Traced to a firm

83

Firms

40

Updated

September 2026

Asked at

All firmsAdvent International6Apollo Global Management6Audax Group6Carlyle Group6EQT6Silver Lake6Vista Equity Partners6WPWarburg Pincus6HIH.I.G. Capital5Oaktree Capital Management5Platinum Equity5TPTPG5General Atlantic4AMAres Management3Blackstone3Clayton Dubilier and Rice3GSGuggenheim Securities3Insight Partners3Invesco3Lazard3Neuberger Berman3NUNuveen3TSTruist Securities3Bain Capital2HWHarris Williams2Kohlberg Kravis Roberts2Millennium Management2Moody's2Rothschild & Co2WBWilliam Blair2Bessemer Venture Partners1Citi1Evercore1FTFranklin Templeton1Houlihan Lokey1HPS Investment Partners1KKR1Mizuho1MSMorgan Stanley1Sycamore Partners1

Topic

All topicsLBO mechanics7Value creation5Returns2Fund economics9Investment judgement18Valuation6Firm knowledge2Credit and financing9Operations4Due diligence8Career and fit11Sector knowledge4Accounting2Deal structuring7Industry knowledge3Brainteasers3

Level

AnyCoreIntermediateHard

Type

AnyTechnicalCaseFitMarket viewBrainteaser

1. 063How do you underwrite a software business?Sector knowledgeHardsuperdayVista Equity PartnersPrivate Equity · Austin · 2023Houlihan LokeyInvestment Banking · New York · 2026

   Say this

   Retention first, then pricing power, then sales efficiency. In software the recurring base is the asset, so net revenue retention above 110 percent means the business compounds without selling anything new.

   Then walk it

   1. Build the ARR bridge: opening recurring revenue, plus new, plus expansion, less churn and downgrades. Everything else follows from that roll-forward.
   2. Net revenue retention is the headline. Above 110 percent the installed base grows by itself; below 100 percent you are running to stand still and the growth is all bought.
   3. Then the stickiness behind the number: is the product embedded in a workflow, integrated with systems of record, does it hold the customer's data? Mission-critical software with high switching cost supports pricing.
   4. Pricing is usually the biggest immediate lever in a software buyout. Most vertical software is underpriced relative to the value delivered, and moving to value-based or usage-based pricing on renewal drops straight to margin.
   5. Sales efficiency: CAC payback and the magic number. If payback exceeds 24 months, the problem is targeting or pricing rather than effort, and the fix is reallocation rather than more spend.
   6. Then the cost levers a sponsor pulls: rationalising the product portfolio, consolidating cloud spend, offshoring support and engineering, and cutting R&D on products nobody buys. And the risk to underwrite now is whether AI changes the product's defensibility over the hold period.

   Where candidates lose it

   Treating it as a generic business with good margins. The sector has a specific vocabulary and a specific playbook: ARR bridge, net retention, CAC payback, pricing on renewal. And ignoring the AI disruption question on a five-year hold is a real analytical gap in 2026.

   Expect next

   • What net retention would justify the entry multiple?
   • What does AI do to the defensibility over five years?
   • Where would you take price first?

   Reported by candidates at Vista Equity Partners (Private Equity, Austin, 2023); Houlihan Lokey (Investment Banking, New York, 2026). Source: Wall Street Oasis.

2. 065What would you include in a portfolio right now if you could choose across all asset classes, including fund of funds?Fund economicsHardsuperdayNeuberger BermanPrivate Equity · London · 2022

   Say this

   Start from the objective and the liquidity constraint, not from asset classes. Then take a view on where risk is being compensated today, and build around that with a clear reason for every allocation.

   Then walk it

   1. Frame first: what return is needed, over what horizon, with what drawdown tolerance and what liquidity requirement. A twenty-year endowment and a five-year corporate pot get completely different answers.
   2. Then the relative value view. With cash and high-grade credit offering a real yield, the bar for taking equity and illiquidity risk is higher than it was for the previous decade, and the allocation should say so explicitly.
   3. Within private markets: favour strategies where the return does not depend on cheap leverage or multiple expansion. Private credit and operationally-driven mid-market buyout have a better case than large-cap financial engineering.
   4. Secondaries deserve a specific mention: they buy mature assets at a discount, shorten the J-curve, and give vintage diversification. In a slow exit environment, supply of secondary stakes is elevated, which is a genuine opportunity.
   5. Fund of funds: justify it or do not use it. It adds a fee layer, so it only makes sense for an investor without the team to select and access managers directly, or for accessing capacity-constrained funds.
   6. Then say what you are deliberately underweighting and why, and name the risk to the whole construction. An allocation with no underweights and no identified risk is not a view.

   Where candidates lose it

   Producing a balanced textbook allocation with no view and no reasoning about current pricing. And including fund of funds without addressing the double fee layer, which is the obvious challenge the interviewer will make.

   Expect next

   • Why fund of funds rather than direct?
   • What are you underweighting?
   • How would you assess a fund's performance before committing?

   Reported by candidates at Neuberger Berman (Private Equity, London, 2022). Source: Wall Street Oasis.

3. 075What happens if a portfolio company breaches a covenant?Credit and financingHardsuperdayRestructuringPrivate credit

   Say this

   It is a technical default, which gives lenders the right to accelerate but rarely leads to them doing so. In practice it starts a negotiation, and the sponsor's leverage in that negotiation depends on whether it is willing to inject equity.

   Then walk it

   1. First, the legal position: a breach gives lenders the right to call the debt. They almost never do, because accelerating a business that is still operating usually destroys value for them too.
   2. So it becomes a negotiation. The standard outcomes are a waiver for one testing period, an amendment resetting the covenant levels, or an amend-and-extend that also pushes the maturity.
   3. The price of a waiver: an amendment fee, a higher margin, tighter covenants going forward, and often additional information rights or a requirement for an independent business review.
   4. The equity cure is the key sponsor tool. Most credit agreements allow the sponsor to inject equity that is deemed to count as EBITDA for covenant purposes, curing the breach. There are limits on how many times it can be used and in consecutive periods.
   5. The sponsor's decision is whether the business is worth more equity. If the equity is already worth nothing, the rational move is to hand the keys over and let lenders take control, and everyone in the negotiation knows that.
   6. The behaviour that matters most is timing: tell lenders early, before the test date, with a plan. A sponsor that surprises its lenders gets much worse terms than one that pre-negotiates.

   Where candidates lose it

   Assuming a breach means immediate enforcement. It almost never does. The examinable content is the waiver-or-amend negotiation, the equity cure mechanism, and the fact that the sponsor's willingness to put in more money is what determines the outcome.

   Expect next

   • What is an equity cure and what are its limits?
   • When would you hand the keys over?
   • How does covenant-lite change this?
4. 080Would you have done the deal you worked on, at that price?Career and fitHardsuperdayEvercoreInvestment Banking · Menlo Park · 2025EQTLeveraged Buyouts · Germany · 2018

   Say this

   Take a position. The question is whether you form independent views or just execute instructions, so the worst answer is that the client decided and it was not your place to have an opinion.

   Then walk it

   1. State your view in the first sentence: yes at that price, no at that price, or yes but only with a different structure.
   2. Then the reason in investment terms: what you would have needed to believe, and whether you believed it. 'At 14 times against peers at 11, the buyer needed the full synergy case to land, and I thought the revenue synergies were aspirational' is a real answer.
   3. Then the specific thing that would have changed your mind, which shows the view is considered rather than reflexive.
   4. Acknowledge what you could not see: the buyer had diligence you did not, and there may have been strategic reasons outside the model. That is accuracy, not hedging, as long as you still commit to a view.
   5. If you would have done it, say what you liked and what you would have watched during the hold. A positive answer needs as much substance as a negative one.
   6. The framing that works: answer as though you had to defend it to an investment committee, because that is exactly the skill being assessed.

   Where candidates lose it

   Deferring to the client's judgement. Bankers moving to the buy side fail on this constantly, and it is the single clearest signal of whether someone thinks like a principal or an adviser. Have a view on every deal on your resume.

   Expect next

   • What price would you have paid?
   • What would have made you walk?
   • Which of our portfolio companies would you not have bought?

   Reported by candidates at Evercore (Investment Banking, Menlo Park, 2025); EQT (Leveraged Buyouts, Germany, 2018). Source: Wall Street Oasis.

5. 081How would you value a business with negative EBITDA that a sponsor is still interested in?ValuationHardtechnicalPlatinum EquityGeneralist · Los Angeles · 2014

   Say this

   Value it on normalised or post-turnaround earnings, and cross-check against asset value. The question is not what it earns today but what it earns once the fixable problems are fixed, and what it is worth if they are not.

   Then walk it

   1. First diagnose why EBITDA is negative. Cyclical trough, a fixable cost problem, a loss-making division dragging a profitable core, or genuine structural decline. Only the first three are investable.
   2. Build normalised EBITDA: strip out the loss-making division, add back the cost the business should not be carrying, and assume mid-cycle volumes. That gives you an earnings base to apply a multiple to.
   3. Then value the downside on assets: what are the receivables, inventory, property and equipment worth in an orderly liquidation? For a turnaround, asset value is the floor and it is often what makes the deal safe.
   4. Then the cash requirement, which is the thing that kills turnarounds. How much cash does the business burn before it breaks even, and is that funded? A turnaround that runs out of money at month fourteen fails regardless of the thesis.
   5. Structure follows: often a low or nominal purchase price, sometimes the seller paying you to take it, with the real investment being the capital injected afterwards. Platinum Equity built a business on exactly this.
   6. So the honest framing: you are not buying earnings, you are buying an asset base and an option on a turnaround, and the price should reflect the probability that the turnaround works.

   Where candidates lose it

   Trying to apply a multiple to a negative number. The answer is normalised earnings plus an asset floor, and crucially the cash burn to breakeven, which is what determines whether the deal is survivable.

   Expect next

   • How much cash would you need to fund it?
   • When would you walk away from a turnaround?
   • How do you tell a cyclical trough from structural decline?

   Reported by candidates at Platinum Equity (Generalist, Los Angeles, 2014). Source: Wall Street Oasis.

6. 085How would you think about a take-private of a listed company?Investment judgementHardsuperdayLarge-cap private equity

   Say this

   You need a premium the board can accept, a reason the company is better off private, and financing for a much larger cheque. The premium is the hurdle: you are paying 25 to 35 percent above the market's own view before you start.

   Then walk it

   1. The premium problem: public shareholders need a meaningful premium to sell, typically 25 to 35 percent. So your entry value is materially above where the market prices it, and the value creation has to cover that before you earn anything.
   2. The reason to go private has to be real: a long-term restructuring that would destroy quarterly earnings, heavy investment that public markets will not fund, a break-up that requires patience, or an undervalued asset the market persistently misprices because it is too small or too complex to cover.
   3. Process constraints are severe. There is a regulatory regime around disclosure and timing, a board with fiduciary duties, a go-shop period in many jurisdictions, and the risk of an interloper once your bid is public.
   4. Diligence is limited compared with a private deal. You get what the board gives you in a confidential process, and public disclosure is your base.
   5. Financing is larger and usually needs a club of sponsors or a substantial equity cheque, and the financing must be committed before you can announce.
   6. And the shareholder dynamics: index funds, activists, and a founder or family with a blocking stake all change the calculus. A supportive large holder can make the deal; a hostile one can kill it.

   Where candidates lose it

   Treating it as a normal buyout with a bigger number. The premium is the defining economic feature and the process and disclosure constraints are the defining practical ones. Both should appear.

   Expect next

   • How do you justify the premium?
   • What is a go-shop?
   • How do you handle an activist on the register?

Firm tags come from public, anonymous candidate reports on Wall Street Oasis: strong signal, not sworn testimony. Firms are named as the places a question was reported, not as partners of Fin Maverick. Answers are written for this page to show how to think out loud; they are not scripts to recite.